Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Given Consensus Rating of "Moderate Buy" by Brokerages

Key Points

• Zai Lab has a “Moderate Buy” consensus rating among seven analysts, with four buy ratings, one strong buy, one hold and one sell. The average 12-month price target is $37.25.
• Citigroup raised its price target to $45 and maintained a buy rating, while other analysts moved their views from strong sell to hold or from sell to a less negative rating.
• Zai Lab reported quarterly revenue of $106.31 million and an EPS loss of $0.50; analysts expect a full-year loss of $2.37 per share. Shares opened at $26.41, while insiders sold 43,218 shares worth approximately $833,000 over the past quarter.

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Get Free Report) has earned an average rating of "Moderate Buy" from the seven analysts that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokers that have covered the stock in the last year is $37.25.

ZLAB has been the topic of a number of recent research reports. Weiss Ratings upgraded Zai Lab from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Wednesday, July 29th. Zacks Research raised Zai Lab from a "strong sell" rating to a "hold" rating in a research note on Tuesday, July 7th. Finally, Citigroup lifted their price target on Zai Lab from $44.00 to $45.00 and gave the company a "buy" rating in a report on Friday, August 7th.

Insider Activity at Zai Lab

In other Zai Lab news, CFO Yajing Chen sold 2,264 shares of Zai Lab stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $17.46, for a total value of $39,529.44. Following the completion of the sale, the chief financial officer directly owned 35,691 shares in the company, valued at $623,164.86. The trade was a 5.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director William Lis sold 8,506 shares of the business's stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $25.00, for a total transaction of $212,650.00. Following the completion of the sale, the director directly owned 41,931 shares of the company's stock, valued at $1,048,275. This represents a 16.86% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 43,218 shares of company stock valued at $833,387. 4.88% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Zai Lab

A number of large investors have recently bought and sold shares of ZLAB. Nykredit A S bought a new position in Zai Lab during the second quarter valued at about $79,000. Seven Fleet Capital Management LP boosted its stake in shares of Zai Lab by 74.7% during the 2nd quarter. Seven Fleet Capital Management LP now owns 136,016 shares of the company's stock worth $2,584,000 after acquiring an additional 58,158 shares in the last quarter. Finally, Headlands Technologies LLC boosted its stake in shares of Zai Lab by 142.0% during the 2nd quarter. Headlands Technologies LLC now owns 68,010 shares of the company's stock worth $1,292,000 after acquiring an additional 39,901 shares in the last quarter. 41.65% of the stock is currently owned by institutional investors.

Zai Lab Stock Down 0.1%

Shares of NASDAQ:ZLAB opened at $26.41 on Wednesday. The firm has a fifty day moving average of $23.49 and a two-hundred day moving average of $20.86. The firm has a market capitalization of $3.00 billion, a P/E ratio of -15.44 and a beta of 0.83. Zai Lab has a 12-month low of $15.96 and a 12-month high of $34.72.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last posted its quarterly earnings results on Tuesday, June 30th. The company reported ($0.50) earnings per share for the quarter. Zai Lab had a negative return on equity of 27.43% and a negative net margin of 41.86%.The company had revenue of $106.31 million during the quarter. Equities research analysts expect that Zai Lab will post -2.37 earnings per share for the current fiscal year.

About Zai Lab

Zai Lab Limited is a biopharmaceutical company focused on discovering, developing and commercializing medicines for significant unmet medical needs. The company's research and development activities have centered on oncology, autoimmune and inflammatory diseases, infectious diseases, and neuroscience. Zai Lab operates through a combination of internally developed programs and collaborations with global pharmaceutical and biotechnology companies.

The company has built a commercial portfolio in Greater China that has included ZEJULA (niraparib), a PARP inhibitor used in certain ovarian cancer settings; QINLOCK (ripretinib), a treatment for gastrointestinal stromal tumors; and NUZYRA (omadacycline), an antibiotic for certain bacterial infections.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.